1. Home
  2. SPTN vs MLYS Comparison

SPTN vs MLYS Comparison

Compare SPTN & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPTN
  • MLYS
  • Stock Information
  • Founded
  • SPTN 1917
  • MLYS 2019
  • Country
  • SPTN United States
  • MLYS United States
  • Employees
  • SPTN N/A
  • MLYS N/A
  • Industry
  • SPTN Food Distributors
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • SPTN Consumer Discretionary
  • MLYS Health Care
  • Exchange
  • SPTN Nasdaq
  • MLYS Nasdaq
  • Market Cap
  • SPTN 618.4M
  • MLYS 634.6M
  • IPO Year
  • SPTN N/A
  • MLYS 2023
  • Fundamental
  • Price
  • SPTN $17.92
  • MLYS $9.97
  • Analyst Decision
  • SPTN Hold
  • MLYS Strong Buy
  • Analyst Count
  • SPTN 1
  • MLYS 2
  • Target Price
  • SPTN $20.00
  • MLYS $30.00
  • AVG Volume (30 Days)
  • SPTN 264.2K
  • MLYS 254.8K
  • Earning Date
  • SPTN 02-13-2025
  • MLYS 03-20-2025
  • Dividend Yield
  • SPTN 4.86%
  • MLYS N/A
  • EPS Growth
  • SPTN 9.92
  • MLYS N/A
  • EPS
  • SPTN 1.33
  • MLYS N/A
  • Revenue
  • SPTN $9,532,883,000.00
  • MLYS N/A
  • Revenue This Year
  • SPTN N/A
  • MLYS N/A
  • Revenue Next Year
  • SPTN $2.15
  • MLYS N/A
  • P/E Ratio
  • SPTN $13.48
  • MLYS N/A
  • Revenue Growth
  • SPTN N/A
  • MLYS N/A
  • 52 Week Low
  • SPTN $17.30
  • MLYS $8.58
  • 52 Week High
  • SPTN $23.00
  • MLYS $16.91
  • Technical
  • Relative Strength Index (RSI)
  • SPTN 43.03
  • MLYS 40.13
  • Support Level
  • SPTN $17.68
  • MLYS $9.18
  • Resistance Level
  • SPTN $18.38
  • MLYS $10.71
  • Average True Range (ATR)
  • SPTN 0.38
  • MLYS 0.84
  • MACD
  • SPTN 0.04
  • MLYS -0.05
  • Stochastic Oscillator
  • SPTN 57.41
  • MLYS 28.72

About SPTN SpartanNash Company

SpartanNash Co is a food solutions company that delivers the ingredients. Its principal business activities include, distributing grocery products to a diverse group of independent and chain retailers, its corporate-owned retail stores, and U.S. military commissaries and exchanges; as well as operating a fresh produce distribution network and the Our Family private label brand. The company operates in two segments: Retail and Wholesale. Majority of the revenue is earned from its Wholesale segment which uses a multi-channel sales approach to distribute national brand and private brand products to independent retailers, national accounts, food service distributors, e-commerce providers, and the Company's corporate owned retail stores.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

Share on Social Networks: